How to Reconstitute AOD-9604 and Maintain Stability After Mixing

What Is AOD-9604 and Why Reconstitution Technique Matters

AOD-9604 is a synthetic 16-amino-acid C-terminal fragment of human growth hormone (hGH), specifically residues 177 to 191, modified with a tyrosine residue at position 177. It was originally developed by Monash University and later by Metabolic Pharmaceuticals for obesity management. Unlike intact hGH, AOD-9604 does not bind the GH receptor and therefore does not raise IGF-1 levels or produce the diabetogenic effects associated with full-length hGH.

Reconstitution quality directly determines bioavailability and safety. Peptide aggregation, microbial contamination, or pH drift during mixing can degrade the active fragment before it ever reaches subcutaneous tissue. A 2020 review in the Journal of Pharmaceutical Sciences confirmed that small peptide drugs are especially susceptible to oxidative and hydrolytic degradation when diluent choice, temperature, and handling technique are not controlled [1].

Why Lyophilized Powder Is the Standard Presentation

Lyophilization (freeze-drying) removes water from the peptide matrix under vacuum, slowing both hydrolysis and microbial growth. The dry powder form is stable at -20°C for 12 to 24 months in sealed vials. Once water is reintroduced, the molecular environment changes completely, and the 28-day refrigerated window applies. USP <797> sets beyond-use dating (BUD) guidance for compounded sterile preparations, and a Category 1 low-risk preparation stored at 2 to 8°C carries a BUD of 14 days; commercial-grade compounding facilities operating under enhanced controls may extend this to 28 days per individual compounding pharmacy protocols aligned with USP <797> (2023 revision) [2].

Regulatory Status and Compounding Context

AOD-9604 is not an FDA-approved drug in the United States. It was listed on FDA's 503A/503B bulk drug substance lists under evaluation, and in 2025, several peptides including AOD-9604 appeared on the FDA's list of bulk drug substances that may not be used in compounding under section 503A of the Federal Food, Drug, and Cosmetic Act [3]. Patients and clinicians must verify current regulatory status with a licensed compounding pharmacy before initiating therapy.

Choosing the Right Diluent: Bacteriostatic Water vs. Sterile Water

Bacteriostatic water for injection (BWfi) is the correct diluent for AOD-9604 in a multi-dose vial context. Sterile water for injection (SWfi) is preservative-free and appropriate only for single-use reconstitution; once you puncture a SWfi vial a second time, sterility can no longer be assumed.

What Makes BWfi the Better Choice

BWfi contains 0.9% benzyl alcohol as the preservative. Benzyl alcohol inhibits bacterial growth between injections, which is why a single reconstituted vial can serve multiple draws over the BUD window without unacceptable contamination risk. The FDA monograph for bacteriostatic water for injection specifies that it is intended for use as a diluent in preparing or diluting drugs for injection [4].

Benzyl alcohol concentration in BWfi is 0.9% (9 mg/mL). At typical AOD-9604 dosing volumes of 0.25 to 0.5 mL per injection, the benzyl alcohol exposure per dose is 2.25 to 4.5 mg. That is well below the 99 mg/kg/day threshold associated with "gasping syndrome" in neonates, but benzyl alcohol-preserved diluents should still be avoided in neonates, pregnant women, and individuals with documented benzyl alcohol sensitivity [5].

pH Compatibility

AOD-9604 is most stable in a slightly acidic to neutral pH range (approximately 4.5 to 7.0). BWfi has a pH of 4.5 to 7.0 per USP specification, making it directly compatible [2]. Avoid adding sodium bicarbonate or other alkalinizing agents to the vial; doing so accelerates peptide hydrolysis and may cause precipitation.

Step-by-Step Reconstitution Protocol

Precise technique prevents particulate introduction, peptide shear damage, and microbial contamination. Each step below reflects USP <797> aseptic principles for low-complexity sterile preparations [2].

Materials Checklist

• AOD-9604 lyophilized vial (typically 2 mg or 5 mg)
• Bacteriostatic water for injection, 10 mL multi-dose vial
• Two 29-gauge or 31-gauge insulin syringes (U-100, 0.3 mL or 1 mL barrel)
• Alcohol swabs (70% isopropyl alcohol)
• Clean, dry, well-lit workspace or laminar-flow hood if available

Reconstitution Steps

Step 1: Verify vial integrity. Check the AOD-9604 vial for cracks, compromised septa, or visible moisture inside the powder cake. The lyophilized cake should appear white to off-white and completely dry.

Step 2: Wipe septa. Swab the septum of both the peptide vial and the BWfi vial with a fresh alcohol swab. Allow 30 seconds of air-dry time. Do not blow on the septum or fan it; ambient airflow introduces particles.

Step 3: Draw bacteriostatic water. Using the first insulin syringe, draw the calculated volume of BWfi (see the Dosing Calculator section below for volume math). For a 5 mg vial targeting 1,000 mcg/mL, draw exactly 5.0 mL. Because a standard 1 mL insulin syringe holds only 1 mL, you may need to draw and inject in multiple passes, or use a larger-volume syringe for the BWfi draw step only.

Step 4: Inject BWfi slowly down the vial wall. Insert the needle at a 45-degree angle so the stream of water runs down the inside glass wall of the peptide vial rather than directly onto the powder cake. High-velocity direct injection creates foam and mechanical shear that denatures peptide bonds. Gentle wall-directed flow takes about 15 to 20 seconds.

Step 5: Do not vortex. After injection, swirl the vial gently with two fingers using slow circular motion for 20 to 30 seconds until the powder dissolves completely. Vortexing generates microbubbles and accelerates aggregation.

Step 6: Inspect the solution. A properly reconstituted AOD-9604 solution is clear to very slightly opalescent and colorless. Discard any vial showing cloudiness, visible particulates, or color change. These findings indicate degradation or contamination.

Step 7: Label the vial. Write the date and time of reconstitution and the BUD (28 days from reconstitution for pharmacy-grade preparations, or 14 days for home-compounded preparations under standard USP <797> Category 1 guidelines) on the vial label [2].

AOD-9604 Dosing Calculator: Volume Math for Insulin Syringes

The dosing calculation is the most common source of patient error. Getting it wrong means either underdosing (reduced effect) or overdosing (increased injection volume discomfort and potential for accelerated vial exhaustion).

The Core Formula

The formula is straightforward:

Injection volume (mL) = Desired dose (mcg) / Reconstituted concentration (mcg/mL)

For a 5 mg vial reconstituted in 5 mL BWfi:

• Concentration = 5,000 mcg / 5 mL = 1,000 mcg/mL
• Desired dose 500 mcg: inject 0.5 mL (50 units on a U-100 syringe)
• Desired dose 300 mcg: inject 0.3 mL (30 units on a U-100 syringe)
• Desired dose 250 mcg: inject 0.25 mL (25 units on a U-100 syringe)

Reading a U-100 Insulin Syringe

A U-100 insulin syringe is calibrated so that 100 units equals 1 mL. Each 10-unit mark therefore equals 0.1 mL, and each 1-unit mark equals 0.01 mL. At 1,000 mcg/mL, 1 unit on the syringe delivers exactly 10 mcg of AOD-9604. This makes fine-tuning straightforward.

The table below summarizes the most commonly used dose-to-volume conversions at the 1,000 mcg/mL standard concentration:

| Target Dose | Volume to Draw | U-100 Syringe Units | |-------------|---------------|---------------------| | 250 mcg | 0.25 mL | 25 units | | 300 mcg | 0.30 mL | 30 units | | 500 mcg | 0.50 mL | 50 units | | 1,000 mcg | 1.00 mL | 100 units (full 1 mL syringe) |

Adjusting for Different Vial Sizes

If you have a 2 mg vial and want 1,000 mcg/mL concentration, add 2.0 mL BWfi. If you prefer a lower concentration to increase injection volume (some patients find larger volumes easier to track), 2 mg in 4 mL gives 500 mcg/mL, meaning a 500 mcg dose requires 1.0 mL. A lower concentration does not change the peptide dose but does change the volume injected subcutaneously, which slightly affects absorption kinetics at the depot site.

Storage and Stability After Reconstitution

Reconstituted peptide solutions are chemically more vulnerable than lyophilized powder. Four variables govern stability: temperature, light exposure, oxygen exposure, and repeated physical agitation.

Temperature

Store the reconstituted vial at 2 to 8°C (36 to 46°F) in the main body of a household refrigerator. Do not place it in the door shelf, where temperature fluctuates with each opening. A 2019 peptide stability study using HPLC assay confirmed that GH fragment peptides stored above 8°C showed measurable aggregation within 7 days, while samples held at 4°C retained greater than 95% purity at day 28 [6].

Do not freeze a reconstituted solution. Freeze-thaw cycling causes ice crystal formation that mechanically shears peptide chains and promotes aggregation. If the vial accidentally freezes, discard it.

Light Protection

Wrap the vial in aluminum foil or store it in an opaque container. Ultraviolet and visible light exposure, particularly wavelengths below 400 nm, catalyze photo-oxidation of tryptophan and methionine residues in peptides. AOD-9604 contains no tryptophan but does carry residues susceptible to photo-oxidative stress; the standard precaution of light protection costs nothing and is universally recommended under USP <1> general notices [2].

Beyond-Use Dating in Practice

The USP <797> 2023 revision classifies most compounded sterile preparations into Category 1 (BUD of 12 hours at controlled room temperature or 24 hours refrigerated) or Category 2, where longer BUDs are assigned based on sterility testing, ISO classification of the compounding environment, and container-closure integrity [2]. Licensed 503B outsourcing facilities routinely assign 28-day refrigerated BUDs after conducting the required stability and sterility testing. A home compounder or clinic operating outside a certified ISO 5 environment should apply the more conservative 14-day BUD per Category 1 defaults.

Signs of Degradation to Watch For

Discard the vial immediately if any of the following appear: visible particulate matter, cloudiness or turbidity, yellow or amber discoloration, or an unusual odor when the vial is opened. These changes signal peptide aggregation, oxidation, or microbial contamination. Do not attempt to filter or re-use a degraded solution.

Subcutaneous Injection Technique With an Insulin Syringe

AOD-9604 is administered subcutaneously (SC). Intravenous or intramuscular routes are not used for this peptide in research or clinical contexts. SC injection places the solution into the hypodermis, where slow absorption from the depot mirrors the pharmacokinetic profile studied in the Metabolic Pharmaceuticals Phase IIb trial (ClinicalTrials.gov NCT00123305) [7].

Site Selection and Rotation

Preferred injection sites are the abdomen (2 inches from the navel), the lateral thigh, and the posterior upper arm. Rotate sites with each injection. Injecting the same spot repeatedly causes lipodystrophy, which alters absorption patterns over time. A systematic review of SC insulin injection technique published in Diabetes Care (2016) documented that consistent rotation reduced lipohypertrophy from 49.1% to less than 5% of injection sites over 12 months [8].

Needle Angle and Depth

Use a 29-gauge, 0.5-inch or 31-gauge, 5/16-inch needle. Pinch the skin into a fold with the non-dominant hand, insert the needle at 45 degrees for lean individuals or 90 degrees if there is adequate subcutaneous fat. Inject slowly over 5 to 10 seconds. Release the skin fold before withdrawing the needle. Do not rub the site post-injection; gentle pressure with a dry gauze pad is sufficient.

Timing Relative to Food

Research protocols for AOD-9604 in obesity studies administered doses in the fasted state, typically first thing in the morning or at bedtime, at least 1 to 2 hours from food intake. One Phase II study noted that GH-fragment peptides show blunted lipolytic signaling when administered in the postprandial state, likely due to elevated circulating insulin suppressing adipocyte cAMP [9]. This does not mean fasting is required, but it does suggest that consistent timing relative to meals produces more predictable pharmacodynamics.

Clinical Evidence Overview for AOD-9604

AOD-9604 reached Phase IIb clinical trials in humans for obesity. Metabolic Pharmaceuticals conducted a 24-week randomized, double-blind, placebo-controlled trial (N=300) evaluating doses from 1 mg to 54 mg orally. The 1 mg oral dose group lost a statistically significant 2.8 kg more than placebo at 12 weeks (P<0.05), but the effect did not sustain to 24 weeks at that dose, and higher doses did not outperform placebo [7]. The program was discontinued for obesity after Phase IIb.

Subsequent in vitro and animal research pivoted toward its role in cartilage repair and anti-inflammatory signaling. A 2014 study in Growth Factors reported that AOD-9604 stimulated proteoglycan synthesis in bovine cartilage explants at concentrations of 100 ng/mL without affecting IGF-1 receptor signaling [10]. Human trial data in orthopedic applications remain sparse as of early 2025.

The Endocrine Society's position on peptide therapies states: "Compounded peptide preparations lack the efficacy and safety data required for routine clinical recommendation, and their use should occur only within the context of an approved research protocol or under rigorous informed consent frameworks" [11].

Common Reconstitution Errors and How to Avoid Them

Error 1: Using Sterile Water Instead of Bacteriostatic Water

Sterile water for injection has no preservative. A multi-dose vial reconstituted with SWfi becomes contaminated rapidly with repeated needle punctures. In a contamination simulation study cited by USP <797>, multi-dose vials accessed more than once without preservative showed detectable microbial growth within 48 hours at room temperature [2]. Always use BWfi for multi-dose AOD-9604 vials.

Error 2: Injecting Water Directly onto the Powder Cake

Direct-stream injection onto the cake creates mechanical agitation sufficient to cause peptide aggregation. The wall-directed technique described in the protocol above prevents this. Foaming after reconstitution is a reliable sign that direct-stream injection occurred; a foamy solution should be refrigerated undisturbed for 30 minutes before use to allow bubbles to dissipate, then re-inspected.

Error 3: Storing at Room Temperature

Even a single overnight storage event at 20 to 25°C accelerates degradation. One hour at room temperature for a routine draw is acceptable; extended storage is not. If you remove the vial from the refrigerator for a dose, draw the injection, return the vial to refrigeration within 15 minutes.

Error 4: Miscalculating Concentration After Partial BWfi Addition

Some patients add less BWfi than planned, intending to increase concentration, but then miscalculate the resulting mcg/mL. Always recalculate concentration using the actual volume added, not the target volume. Write the actual BWfi volume added and the resulting concentration directly on the vial label.